Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives

使用 213Bi、225Ac 和 227Th 标记的 α 黑素细胞刺激激素 (alphaMSH) 衍生物开发用于黑色素瘤治疗的靶向 α 疗法 (TAT) 放射性药物

• 批准号: 462426
• 负责人: Yang Hua
• 金额: $ 43.47万
• 依托单位: Simon Fraser University (Burnaby, B.C.)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2026-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462426&lang=en
• 关键词: A-Melanocyte-Stimulating Hormone; Alpha Particle Emitting Radionuclides; Melanocortin 1 Receptor; Melenoma Treatment; Radiochemistry Development; Radiopharmaceutical Development; Targeted Radionuclide Therapy

Radioactive atoms that emitting alpha-particles, so called alpha-emitters, are powerful weapons for late-stage cancer treatments. Those radionuclides can deposit a lot of energy in a short distance. When delivered specifically to the tumours, so called ta

发射阿尔法粒子的放射性原子，即所谓的阿尔法发射体，是晚期癌症治疗的强大武器。这些放射性核素可以在短距离内储存大量能量。当特定地传递给肿瘤时，即所谓的ta